Biology subjects

Crosnier, C.

Publications and source records attributed to Crosnier, C..

4 recordsLinked to original sources

bioRxiv2026

Schistosoma mansoni Granulin binds the human neutrophil receptor CD177 and modulates neutrophil activation

To establish chronic infection in the vasculature of their infected host, schistosomes have developed multifaceted strategies of immune subversion. Extracellular parasite proteins are believed to play immunomodulatory functions, but their mode of action remains largely elusive. To investigate whether proteins secreted by the Schistosoma mansoni parasite have the potential to directly interact with host immune receptors, we performed a large-scale protein:protein interaction study between selected parasite proteins sharing structural similarities with known host immune effectors and a protein array of over 750 full-length human ectodomains mostly expressed by immune cells. We identified CD177 as a neutrophil receptor for S. mansoni Granulin (SmGrn). SmGrn exclusively bound the surface of CD177+ human neutrophils and led to cellular hyporesponsiveness following stimulation with LPS as evidenced by decreases in surface markers of activation, delayed reactive oxygen species production and reduced IL-8 release. In addition, human neutrophils exposed to SmGrn showed delayed apoptosis and morphological changes compatible with a more quiescent state as well as transcriptional upregulation of negative regulators of interferon signalling. These data suggest that SmGrn dampens human neutrophil response to stimulation and may lead to suboptimal function during schistosome infection.

immunology↗

bioRxiv2023

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

Plasmodium falciparum RH5 is the most advanced blood-stage malaria vaccine candidate and is under evaluation for efficacy in endemic regions, emphasizing the need to study the underlying antibody response to RH5 during natural infection. Here, we found that RH5-reactive B cells were rare in malaria-exposed individuals despite repeated infections over multiple years. RH5-specific monoclonal antibodies isolated from these individuals were extensively mutated but mostly targeted non-neutralizing epitopes, in contrast to antibodies from RH5-vaccinated, malaria-naive individuals. However, infection-derived MAD8-151 and MAD8-502 were among the most potent neutralizers out of 186 antibodies isolated from both cohorts and target the same epitopes as the most effective vaccine-induced antibodies. Binding to basigin receptor-proximal epitopes was the primary factor governing the potency of RH5-specific antibodies from both natural infection and vaccination, followed by the strength of binding. These results indicate a clear strategy for the development of next-generation RH5 vaccines for use in malaria-endemic regions.

immunology↗

bioRxiv2021

An invariant Trypanosoma vivax vaccine antigen inducing protective immunity

Trypanosomes are protozoan parasites that cause infectious diseases including human African trypanosomiasis (sleeping sickness), and nagana in economically-important livestock animals1,2. An effective vaccine against trypanosomes would be an important control tool, but the parasite has evolved sophisticated immunoprotective mechanisms including antigenic variation3 that present an apparently insurmountable barrier to vaccination. Here we show using a systematic genome-led vaccinology approach4 and a murine model of Trypanosoma vivax infection5 that protective invariant subunit vaccine antigens can be identified. Vaccination with a single recombinant protein comprising the extracellular region of a conserved cell surface protein localised to the flagellum membrane termed "invariant flagellum antigen from T. vivax" (IFX) induced long-lasting protection. Immunity was passively transferred with immune serum, and recombinant monoclonal antibodies to IFX could induce sterile protection and revealed multiple mechanisms of antibody-mediated immunity, including a major role for complement. Our discovery identifies a vaccine candidate for an important parasitic disease that has constrained the socioeconomic development of sub-Saharan African countries6 and challenges long-held views that vaccinating against trypanosome infections cannot be achieved.

microbiology↗

bioRxiv2019

A library of cell-surface and secreted proteins from Schistosoma mansoni identifies early serological markers of infection

Schistosomiasis is a major global health problem caused by blood-dwelling parasitic worms and is currently treated by the mass administration of the drug praziquantel. Appropriate drug treatment strategies are informed by diagnostics that establish the prevalence and intensity of infection, which, in regions of low transmission should be highly sensitive. To identify sensitive new serological markers of Schistosoma mansoni infections, we have compiled a recombinant protein library of 115 parasite cell surface and secreted proteins expressed in mammalian cells. The vast majority of them were shown to be immunoreactive and to contain heat-labile conformational epitopes when tested against pooled human sera from endemic regions. After probing the library against a time series of sera samples from experimental infections in mice, we identified several markers of infection, the majority of which belong to the saposin-domain-containing and cathepsin families of proteins. These new markers will be a valuable tool to detect ongoing and previous S. mansoni infections, including in regions of low transmission. We envisage that this new recombinant protein resource will be used in a wide range of cellular and molecular assays to further our understanding of Schistosoma biology.

immunology↗